Episode Details
Back to Episodes
William Blair biotech analyst Andy Hsieh takes stock of the obesity space after attending the 2025 American Diabetes Association's (ADA's) 85th Scientific Sessions in Chicago
Published 1 year, 2 months ago
Description
He discusses data presented at #ADA25 including Eli Lillys Orforglipron and Bimagrumab, Novo Nordisk's CagriSema, and Amgen's MariTide. Plus, thoughts on Viking's program as it enters phase 3.